WO1988007583A1 - Reagent and method for detecting cells with phagocytic activity - Google Patents

Reagent and method for detecting cells with phagocytic activity Download PDF

Info

Publication number
WO1988007583A1
WO1988007583A1 PCT/HU1988/000015 HU8800015W WO8807583A1 WO 1988007583 A1 WO1988007583 A1 WO 1988007583A1 HU 8800015 W HU8800015 W HU 8800015W WO 8807583 A1 WO8807583 A1 WO 8807583A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
weight
reagent
neutral red
phagocytic activity
Prior art date
Application number
PCT/HU1988/000015
Other languages
French (fr)
Inventor
Katalin POLGÁR
György ÁBEL
Ilona HARSÁNYI
László NAGY
Sándor SIPKA
Edit Vaszari
Iván DARÓCZI
Zoltán PAPP
Original Assignee
Reanal Finomvegyszergyár
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reanal Finomvegyszergyár filed Critical Reanal Finomvegyszergyár
Publication of WO1988007583A1 publication Critical patent/WO1988007583A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Definitions

  • the invention relates to a reagent and a method for detecting cells with phagocytic activity.
  • the solution of neutral red in distilled water is of acidic character (the pH of a solution containing 1 mg/ml of neutral red is 3.1), and, owing to its acidity and hypoosmotic effect, this solution strongly damages the cells. None of the aqueous buffer and nutrient solutions utilized in routine clinical practice proved to be appropriate to dissolve neutral red, since after dissolution precipitation occurs. Organic solvents appeared to be less suitable; thus e.g. neutral red in ethanol solution does not give appropriate staining, whereas the dimethyl sulphoxide solution is difficult to sterilize.
  • the invention aims at providing a reagent solution and diagnostic method for detecting cells with phagocytic activity which is easy to apply and gives highly reliable results.
  • a neutral red-containing cytologic reagent solution should be approximately isoosmotic in relation to the potentially pathologic cells. It is also essential that the mixture of the reagent solu tion formed with the sample to be examined (amniotic fluid) should be almost neutral. It has also been observed that lysozyme enzyme significantly increases the stain uptake of the cells, moreover it Increases the stability of the reagent solution, too. Finally it has been found that the reagent solution should contain a saccharide as an energy source for the cells. When a reagent solution storable for a prolonged period of time is to be prepared, preferably a preservative should also be added to the mixture.
  • the invention relates to a neutral red-containing reagent solution for detecting cells with phagocytic activity.
  • the reagent solution according to the invention comprises 0.2-0.8 % by weight of neutral red, 0.1-0.25% by weight of lysozyme, 0.8-2.0 % by weight of sodium chloride, 0.1-0.3 % by weight of a saccharide and optionally 0.02-0.6 % by weight of a preservative in an aqueous solution with a pH of 3.0 to 8.0, preferably 3.5 to 5.0.
  • the invention also relates to a method for detecting cells with phagocytic activity by staining them with neutral red. According to the invention one proceeds as follows: 0.2-0.8 % by weight of neutral red, 0.1-0.25 % by weight of lysozyme, 0.8-2.0 % by weight of sodium chloride, 0.1-0.3 % by weight of a saccharide (preferably glucose) and optionally 0.02-0.6 % by weight of a preservative are dissolved in water, the pH of the solution is adjusted to 3.0-8.0, preferably 3.5-5.0, the solution is sterilized by filtration, thereafter one part by volume of the resulting reagent solution is admixed with 3-8 parts by volume of a sample to be examined, preferably amniotic fluid, and the resulting cell suspension is examined in a haemocytometer in a manner known per se.
  • a saccharide preferably glucose
  • a preservative optionally 0.02-0.6 % by weight of a preservative
  • the reagent solution according to the invention may comprise as saccharide any mono- or disaccharide serving as energy source for the cells.
  • saccharide any mono- or disaccharide serving as energy source for the cells.
  • glucose is particularly preferred.
  • preservative preferably benzole acid and/or polyvinyl alcohol can be used.
  • the haemocytometrie examination of the cell suspension is performed as described in N. Eng. J. Med. 310, 1463 (1984). According to this method the cell suspension treated with the reagent solution is incubated, thereafter centrifuged, the supernatant is discarded, the sediment is admixed with a washing-diluting solution, and then staining is examined in a Btirker chamber.
  • the reagent solution according to the invention is presented preferably as a reagent kit.
  • the reagent kit comprises a reagent solution presented in dosage units (preferably filled into vials) and a washing-diluting solution presented in dosage units (preferably filled into vials), the volume ratio of said dosage units being 1 : (0.5-5).
  • any solution of known composition applied in cytologic examinations for this purpose can be used.
  • Hank's solution [J.H. Hank and R.E. Wallace: Proc. Soc. Exptl. Biol. Med. 71, 196 (1949)] proved to be particularly suitable.
  • the pH of the Hank's solution is adjusted to 7.2-7.4 (preferably to 7.3) with N-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid.
  • the scope of the Invention also extends to the above reagent kit.
  • the major advantage of the invention is that the solutions applied in the examination are stable, those containing a preservative can be stored for at least 12 months without change, and can be presented in an immediately applicable form. Utilizing the reagent solution or reagent kit according to the invention diagnostic work can be performed more quickly and easily than before and the reliability and reproducibllity of the method is superior to those of the known ones.
  • Reagent kit is prepared from the following solutions: I. Reagent solution:
  • 0.1 g of polyvinyl alcohol is dissolved in 45 ml of hot distilled water, the solution is cooled to room temperature, and then 0.8 g of sodium chloride, 0.1 g of glucose, 0.02 g of benzole acid and 0.1 g of lysozyme are added. The pH of the resulting solution is adjusted to 6.9 with 1 molar Trie [tris(hydroaymethylamino-methane)] buffer solution, and then diluted to a final volume of 50 ml with distilled water.
  • washing-diluting solution 4 g of sodium chloride, 0.2 g of potassium chloride, 0.1 g of magnesium sulphate heptahydrate, 0.09 g of calcium chloride dihydrate, 0.03 g of disodium hydrophosphate dihydrate, 0.03 g of potassium dihydrophosphate and 0.5 g of glucose are dissolved in 350 ml of distilled water, and then 0.1 g of benzole acid is added to the solution.
  • the resulting solution is admixed with a solution of 0.175 g of sodium hydrocarbonate in 12.5 ml of distilled water.
  • the volume of the resulting solution is adjusted to 500 ml with distilled water, the solution is sterilized by passing through a G-5 sintered glass filter, and the filtrate is filled into vials each containing 5 ml of the solution.
  • Reagent kit is prepared from the following solutions: I. Reagent solution
  • the reagent solution has the same composition and is prepared in the same way as described in Example 1.
  • the volume of the resulting solution is adjusted to 500 ml with distilled water, thereafter the solution is sterilized by passing through a G-5 sintered glass filter, and the filtrate is filled into vials each containing 5 ml of the solution.
  • Example 3
  • Reagent kit is prepared from the following solutions: I. Reagent solution
  • the reagent solution has the same composition and is prepared in the same way as described in Example 1. II. Washing-diluting solution
  • the solution is admixed with a solution of 0.130 g of sodium hydrocarbonate in 10 ml of distilled water, and the pH of the resulting solution (Hank's solution) is adjusted to 7.3 with 5 ml of a 1 molar aqueous solution of N-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid.
  • the volume of the resulting solution is adjusted to 500 ml with distilled water, the solution is sterilized by passing through a G-5 sintered glass filter, and the filtrate is filled into vials each containing 5 ml of the solution.
  • Reagent kit is prepared from the following solutions:
  • the reagent solution is prepared as described in Example 1 with the difference that 0.8 g of neutral red is applied.
  • the reagent solution is filtered, and the filtrate is filled into vials each containing 1 ml of the solution.
  • the washing-diluting solution has the same composition and is prepared in the same way as described in Example 1.
  • Example 5 Of the reagent kits described in Examples 1 to 4 one vial of the reagent solution and one vial of the washing-diluting solution are utilized for a single examination.
  • Example 5 Of the reagent kits described in Examples 1 to 4 one vial of the reagent solution and one vial of the washing-diluting solution are utilized for a single examination.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ecology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to a neutral red-containing reagent solution for detecting cells with phagocytic activity. The reagent solution according to the invention comprises 0.2-0.8 % by weight of neutral red, 0.1-0.25 % by weight of lysozyme, 0.8-2.0 % by weight of sodium chloride, 0.1-0.3 % by weight of a saccharide and optionally 0.02-0.6 % by weight of a preservative in an aqueous solution with a pH of 3.0-8.0, preferably 3.5-5.0. The invention also relates to a method for detecting cells with phagocytic activity by utilizing a reagent solution of the above composition.

Description

REAGENT AUD METHOD FOR DETECTIHG CELLS WITH PHAGOCYTIC
ACTIVITY
The invention relates to a reagent and a method for detecting cells with phagocytic activity.
One of the major endeavours of medical science is to recognize developmental anomalies of foetl at the earliest possible stage of pregnancy.
It is well known that disorders of neural tube closure can be diagnostized by cell staining, since when such a disorder exists, cells with phagocytic activity appear in the amniotic fluid which can be detected by colour reaction. As staining agent neutral red is applied [N. Eng. J. Med. 310, 1463 (1984)]. Several problems have been emerged, however, when applying this method in the routine clinical diagnostics. It has been observed that the reliability of detection depends to a great extent on the quality of neutral red, i.e. the results obtained differ significantly when neutral red samples originating from different manufacturers are used. It is also difficult to prepare a solution of neutral red applicable for diagnostic purposes. The solution of neutral red in distilled water is of acidic character (the pH of a solution containing 1 mg/ml of neutral red is 3.1), and, owing to its acidity and hypoosmotic effect, this solution strongly damages the cells. None of the aqueous buffer and nutrient solutions utilized in routine clinical practice proved to be appropriate to dissolve neutral red, since after dissolution precipitation occurs. Organic solvents appeared to be less suitable; thus e.g. neutral red in ethanol solution does not give appropriate staining, whereas the dimethyl sulphoxide solution is difficult to sterilize.
The invention aims at providing a reagent solution and diagnostic method for detecting cells with phagocytic activity which is easy to apply and gives highly reliable results.
We have found that a neutral red-containing cytologic reagent solution should be approximately isoosmotic in relation to the potentially pathologic cells. It is also essential that the mixture of the reagent solu tion formed with the sample to be examined (amniotic fluid) should be almost neutral. It has also been observed that lysozyme enzyme significantly increases the stain uptake of the cells, moreover it Increases the stability of the reagent solution, too. Finally it has been found that the reagent solution should contain a saccharide as an energy source for the cells. When a reagent solution storable for a prolonged period of time is to be prepared, preferably a preservative should also be added to the mixture. Based on the above recognitions, the invention relates to a neutral red-containing reagent solution for detecting cells with phagocytic activity. The reagent solution according to the invention comprises 0.2-0.8 % by weight of neutral red, 0.1-0.25% by weight of lysozyme, 0.8-2.0 % by weight of sodium chloride, 0.1-0.3 % by weight of a saccharide and optionally 0.02-0.6 % by weight of a preservative in an aqueous solution with a pH of 3.0 to 8.0, preferably 3.5 to 5.0.
The invention also relates to a method for detecting cells with phagocytic activity by staining them with neutral red. According to the invention one proceeds as follows: 0.2-0.8 % by weight of neutral red, 0.1-0.25 % by weight of lysozyme, 0.8-2.0 % by weight of sodium chloride, 0.1-0.3 % by weight of a saccharide (preferably glucose) and optionally 0.02-0.6 % by weight of a preservative are dissolved in water, the pH of the solution is adjusted to 3.0-8.0, preferably 3.5-5.0, the solution is sterilized by filtration, thereafter one part by volume of the resulting reagent solution is admixed with 3-8 parts by volume of a sample to be examined, preferably amniotic fluid, and the resulting cell suspension is examined in a haemocytometer in a manner known per se.
The reagent solution according to the invention may comprise as saccharide any mono- or disaccharide serving as energy source for the cells. Of the saccharides glucose is particularly preferred. As preservative preferably benzole acid and/or polyvinyl alcohol can be used.
The haemocytometrie examination of the cell suspension is performed as described in N. Eng. J. Med. 310, 1463 (1984). According to this method the cell suspension treated with the reagent solution is incubated, thereafter centrifuged, the supernatant is discarded, the sediment is admixed with a washing-diluting solution, and then staining is examined in a Btirker chamber. For clinical examinations the reagent solution according to the invention is presented preferably as a reagent kit. The reagent kit comprises a reagent solution presented in dosage units (preferably filled into vials) and a washing-diluting solution presented in dosage units (preferably filled into vials), the volume ratio of said dosage units being 1 : (0.5-5).
As washing-diluting solution any solution of known composition applied in cytologic examinations for this purpose can be used. Hank's solution [J.H. Hank and R.E. Wallace: Proc. Soc. Exptl. Biol. Med. 71, 196 (1949)] proved to be particularly suitable. According to a particularly preferred method the pH of the Hank's solution is adjusted to 7.2-7.4 (preferably to 7.3) with N-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid. The scope of the Invention also extends to the above reagent kit.
The major advantage of the invention is that the solutions applied in the examination are stable, those containing a preservative can be stored for at least 12 months without change, and can be presented in an immediately applicable form. Utilizing the reagent solution or reagent kit according to the invention diagnostic work can be performed more quickly and easily than before and the reliability and reproducibllity of the method is superior to those of the known ones.
The invention is elucidated in detail by the aid of the following non-limiting Examples. Example 1
Reagent kit is prepared from the following solutions: I. Reagent solution:
0.1 g of polyvinyl alcohol is dissolved in 45 ml of hot distilled water, the solution is cooled to room temperature, and then 0.8 g of sodium chloride, 0.1 g of glucose, 0.02 g of benzole acid and 0.1 g of lysozyme are added. The pH of the resulting solution is adjusted to 6.9 with 1 molar Trie [tris(hydroaymethylamino-methane)] buffer solution, and then diluted to a final volume of 50 ml with distilled water. A solution of 0.2 g of neutral red (3-amino-7-dimethylamino-2-methyl-phenozine hydrochloride) in 50 ml of distilled water is added to the above solution, the mixture is well stirred, sterilized by passing through a G-5 sintered glass filter, and the filtrate is filled into vials each containing 1 ml of the solution. II. Washing-diluting solution 4 g of sodium chloride, 0.2 g of potassium chloride, 0.1 g of magnesium sulphate heptahydrate, 0.09 g of calcium chloride dihydrate, 0.03 g of disodium hydrophosphate dihydrate, 0.03 g of potassium dihydrophosphate and 0.5 g of glucose are dissolved in 350 ml of distilled water, and then 0.1 g of benzole acid is added to the solution. The resulting solution is admixed with a solution of 0.175 g of sodium hydrocarbonate in 12.5 ml of distilled water. The mixture is well stirred, then the pH of the resulting solution (Hank's solution) is adjusted to 7.3 with 5 ml of a 1 molar aqueous solution of N-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid.
The volume of the resulting solution is adjusted to 500 ml with distilled water, the solution is sterilized by passing through a G-5 sintered glass filter, and the filtrate is filled into vials each containing 5 ml of the solution.
Example 2
Reagent kit is prepared from the following solutions: I. Reagent solution
The reagent solution has the same composition and is prepared in the same way as described in Example 1.
II. Washing-diluting solution
4 g of sodium chloride, 0.2 g of potassium chloride, 0.1 g of magnesium sulphate heptahydrate, 0.03 g of disodium hydrophosphate, 0.03 g of potassium dihydrophosphate, 0.5 g of glucose and 0.09 g of calcium chloride dihydrate are dissolved in 350 ml of distilled water, and 0.5 g of benzolc acid is added to the solution. The resulting solution is admixed with a solution of 2.4 g of sodium hydrocarbonate in 30 ml of distilled water. The mixture is well stirred, then the pH of the resulting solution (Hank's solution) is adjusted to 7.3 with 5 ml of a 1 molar aqueous solution or N-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid.
The volume of the resulting solution is adjusted to 500 ml with distilled water, thereafter the solution is sterilized by passing through a G-5 sintered glass filter, and the filtrate is filled into vials each containing 5 ml of the solution. Example 3
Reagent kit is prepared from the following solutions: I. Reagent solution
The reagent solution has the same composition and is prepared in the same way as described in Example 1. II. Washing-diluting solution
4 g of sodium chloride, 0.2 g of potassium chloride, 0.1 g of magnesium sulphate heptahydrate, 0.03 g of disodium hydrophosphate dihydrate, 0.03 g of potassium dihydrophosphate, 0.5 g of glucose and 0.09 g of calcium chloride dihydrate are dissolved in 350 ml of distilled water, thereafter 0.6 g of sodium benzoate is added to the solution. The solution is admixed with a solution of 0.130 g of sodium hydrocarbonate in 10 ml of distilled water, and the pH of the resulting solution (Hank's solution) is adjusted to 7.3 with 5 ml of a 1 molar aqueous solution of N-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid. The volume of the resulting solution is adjusted to 500 ml with distilled water, the solution is sterilized by passing through a G-5 sintered glass filter, and the filtrate is filled into vials each containing 5 ml of the solution. Example 4
Reagent kit is prepared from the following solutions:
I. Reagent solution
The reagent solution is prepared as described in Example 1 with the difference that 0.8 g of neutral red is applied. The reagent solution is filtered, and the filtrate is filled into vials each containing 1 ml of the solution.
II. Washing-diluting solution
The washing-diluting solution has the same composition and is prepared in the same way as described in Example 1.
Of the reagent kits described in Examples 1 to 4 one vial of the reagent solution and one vial of the washing-diluting solution are utilized for a single examination. Example 5
5 ml of amniotic fluid are admixed with one vial (1 ml) of the reagent solution described in Example 1. The mixture is incubated for 15 minutes, then centrifuged, the supernatant is discarded, and the sediment is admixed with 0.5 to 2.0 ml of the washing-diluting solution described in Example 1. The stained sample is examined in a Bürker chamber.

Claims

What we claim is:
1. A neutral red-containing reagent solution for detecting cells with phagocytic activity, which comprises 0.2-0.8 % by weight of neutral red, 0.1-0.25 % by weight of lysozyme, 0.8-2.0 % by weight of sodium chloride, 0.1-0.3 % by weight of a saccharide and optionally 0.02-0.6 by weight of a preservative in an aqueous solution with a pH of 3.0 to 8.0, preferably 3.5 to 5.0.
2. A reagent solution as claimed in claim 1, in which the saccharide is a mono- or disaccharide serving as energy source for the cells, preferably glucose.
3. A reagent solution as claimed in claim 1 or 2, in which the preservative is benzole acid and/or polyvinyl alcohol.
4. A method for detecting cells with phagocytic activity by staining them with neutral red , characterized in that 0.2-0.8 % by weight of neutral red, 0.1-0.25 % by weight of lysozyme, 0.8-2.0 % by weight of sodium chloride, 0.1-0.3 % by weight of a saccharide, preferably glucose, and optionally 0.02-0.6 % by weight of a preservative are dissolved in water, the pH of the solution is adjusted to 3.0-8.0, preferably 3.5-5.0, the solution is sterilized by filtration, thereafter one part by volume of the resulting reagent solution is admixed with 3-8 parts by volume of a sample to be examined, preferably amniotic fluid, and the resulting cell suspension is examined in a haemocytometer in a manner known per se.
5. Reagent kit for the detection of cells with phagocytic activity, which comprises a reagent solution as claimed in any of claims 1 to 3 presented in dosage units and a washing-diluting solution presented in dosage units, and the volume ratio of said dosage units is
1 : (0.5-5).
6. A reagent kit as claimed in claim 5, which comprises vials containing 1 ml each of the reagent solution and vials containing 5 ml each of the washing-diluting solution.
7. A reagent kit as claimed in claim 5 or 6, which comprises as washing-diluting solution a Hank's solution the pH of which is adjusted to 7.2-7.4 with N-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid.
PCT/HU1988/000015 1987-03-27 1988-03-22 Reagent and method for detecting cells with phagocytic activity WO1988007583A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1340/87 1987-03-27
HU134087A HU197450B (en) 1987-03-27 1987-03-27 Reagent and method for detecting cells of phagocyte activity

Publications (1)

Publication Number Publication Date
WO1988007583A1 true WO1988007583A1 (en) 1988-10-06

Family

ID=10954018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1988/000015 WO1988007583A1 (en) 1987-03-27 1988-03-22 Reagent and method for detecting cells with phagocytic activity

Country Status (5)

Country Link
EP (1) EP0345295A1 (en)
JP (1) JPH03500961A (en)
AU (1) AU1488588A (en)
HU (1) HU197450B (en)
WO (1) WO1988007583A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105651579B (en) * 2015-12-07 2018-10-23 上海太阳生物技术有限公司 A kind of iophenoxic acid naphthol ester enzyme staining reagent kit

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2153673A1 (en) * 1970-10-30 1972-05-04 General Electric Co., Schenectady, N.Y. (V.StA.) Pre-stained blood test slides and methods of making them
DE2240672B1 (en) * 1972-08-18 1974-01-24 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD AND DEVICE FOR COLORING BIOLOGICAL MATERIAL

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2153673A1 (en) * 1970-10-30 1972-05-04 General Electric Co., Schenectady, N.Y. (V.StA.) Pre-stained blood test slides and methods of making them
DE2240672B1 (en) * 1972-08-18 1974-01-24 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD AND DEVICE FOR COLORING BIOLOGICAL MATERIAL

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 96, No. 25, 21 June 1982 (21.06.82), Columbus, Ohio, USA, BENESTAD H.B. et al. "Flow Cytometry of Mouse Bone Marrow Cells Cultured in Vivo or in Vitro", see page 358, column 1, Abstract- No. 213 666r & Exp. Hematol. (Copenhagen) 1982, 10 (4), 343-51. *
The New England Journal of Medicine, Vol. 310, No. 22, 31 May 1984 (31.05.84), "Neutralred Uptake by Amniotic-Fluid Macrophages in Neural-Tube Defects: A Rapid Test", see page 1463, lines 14-16. *

Also Published As

Publication number Publication date
EP0345295A1 (en) 1989-12-13
HUT46145A (en) 1988-09-28
HU197450B (en) 1989-03-28
JPH03500961A (en) 1991-03-07
AU1488588A (en) 1988-11-02

Similar Documents

Publication Publication Date Title
Heirwegh et al. Recent advances in the separation and analysis of diazo-positive bile pigments
Apstein et al. Improved automated lactate determination
Hadžija A simple method for the quantitative determination of muramic acid
EP0240021B1 (en) Fluorescence polarization immunoassay and reagents for use therein
Frasch et al. Competitive inhibition of phlorizin binding by D-glucose and the influence of sodium: a study on isolated brush border membrane of rat kidney
Gold The quantitative spectrophotometric estimation of total sulfated glycosaminoglycan levels formation of soluble alcian blue complexes
US4290774A (en) Purification of lipoprotein cholesterol for use as a cholesterol reference material
Van Der Plank The estimation of sugars in the leaf of the mangold (Beta vulgaris) Methods for the estimation of fructose, glucose and sucrose. II. The use of basic lead acetate, charcoal and yeast to avoid interference by substances other than sugars. III. Note on the application of copper reagents to unclarified extracts. IV. Tests for the presence of raffinose, maltose, galactose and pentose
CA1306676C (en) Lower alcohol sulfate wash solution, test kit and method for the determination of an immunological ligand
EP0001223A2 (en) Latex coated with a polyhydroxy compound, process for the preparation of this latex, immunological reagent containing this latex, process for the preparation of this reagent, application of this reagent, testing procedure utilising this reagent and reagent kit containing this reagent
US3415718A (en) Composition and process for detecting bacteria in urine
Cifonelli et al. Tubidimetric Method for Determination of Yeast Mannan and Glycogen
EP3599244B1 (en) Composition for protein detection
EP0374620A2 (en) Method and means for the determination of maleimide groups
CH659713A5 (en) SPECIFIC BINDING TEST METHOD AND REAGENT COMPOSITION FOR CARRYING OUT THIS METHOD.
WO1994024568A1 (en) Stable aqueous fk506 standards
EP0347139A2 (en) Imidazole leuco dye composition containing 4'-hydroxyacetanilide diagnostic kit and method using same
WO1988007583A1 (en) Reagent and method for detecting cells with phagocytic activity
Izuhara et al. Conformational change of band 3 protein induced by diethyl pyrocarbonate modification in human erythrocyte ghosts
DE2617870A1 (en) PILI OF NEISSERIA GENORRHOEAE AND PROCESS FOR THEIR PRODUCTION
SU416969A3 (en)
STOWARD Studies in fluorescence histochemistry: I. The demonstration of sulphomucins
WO2009017959A1 (en) Method of measurement of micronucleated erythrocyte populations
Kurtin et al. Assay of β-glucuronidase in bile following ion-pair extraction of pigments and bile acids
EP0049849A2 (en) Process for determining streptococcal deoxyribo-nuclease B according to the toluidine-blue O method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR DK FI JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988902576

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988902576

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988902576

Country of ref document: EP